Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies
Brief Summary: The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.


Options:
A: Arm Label: Nivolumab monotherapy (Dose Escalation); Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Nivolumab + Lirilumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Lirilumab | Arm Label: Nivo + Dara + Pom + Dexa vs. Nivo + Dara; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Daratumumab, Drug: Pomalidomide, Drug: Dexamethasone | Arm Label: Daratumumab vs. Nivolumab + Daratumumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Daratumumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Daratumumab vs. Nivolumab + Daratumumab, Nivo + Dara + Pom + Dexa vs. Nivo + Dara, Nivolumab + Ipilimumab, Nivolumab + Lirilumab, Nivolumab monotherapy (Dose Escalation) | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Nivolumab + Ipilimumab | Intervention Type: BIOLOGICAL; Name: Lirilumab; Assigned to Arm(s): Nivolumab + Lirilumab | Intervention Type: BIOLOGICAL; Name: Daratumumab; Assigned to Arm(s): Daratumumab vs. Nivolumab + Daratumumab, Nivo + Dara + Pom + Dexa vs. Nivo + Dara | Intervention Type: DRUG; Name: Pomalidomide; Assigned to Arm(s): Nivo + Dara + Pom + Dexa vs. Nivo + Dara | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Nivo + Dara + Pom + Dexa vs. Nivo + Dara
B: Arm Label: 1x10^9-1x10^10+ high dose Interleukin-2; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Aldesleukin | Arm Label: 1x10^9-1x10^10 + high dose Retreat; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Aldesleukin | Arm Label: 0.5x10^7 cells/kg; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL | Arm Label: 2.5x10^6 cells/kg; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL | Arm Label: 1.0x10^6 cells/kg; Type: EXPERIMENTAL; Interventions: Drug: Fludarabine, Drug: Cyclophosphamide, Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL | Arm Label: 1.0x10^6 cells/kg (Reduced chemo); Type: EXPERIMENTAL; Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: 2.0x10^6 cells/kg (Reduced chemo); Type: EXPERIMENTAL; Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: 6.0x10^6 cells/kg (Reduced chemo); Type: EXPERIMENTAL; Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: 2.0x10^6 cells/kg (Moderate chemo); Type: EXPERIMENTAL; Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Fludarabine, Drug: Cyclophosphamide | Arm Label: 2.0x10^6 cells/kg (9-12 days culture); Type: EXPERIMENTAL; Interventions: Biological: Anti-cluster of differentiation 19 (CD19)-CAR PBL, Drug: Fludarabine, Drug: Cyclophosphamide | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): 0.5x10^7 cells/kg, 1.0x10^6 cells/kg, 1x10^9-1x10^10 + high dose Retreat, 1x10^9-1x10^10+ high dose Interleukin-2, 2.5x10^6 cells/kg | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): 0.5x10^7 cells/kg, 1.0x10^6 cells/kg, 1x10^9-1x10^10 + high dose Retreat, 1x10^9-1x10^10+ high dose Interleukin-2, 2.5x10^6 cells/kg | Intervention Type: BIOLOGICAL; Name: Anti-cluster of differentiation 19 (CD19)-CAR PBL; Assigned to Arm(s): 0.5x10^7 cells/kg, 1.0x10^6 cells/kg, 1.0x10^6 cells/kg (Reduced chemo), 1x10^9-1x10^10 + high dose Retreat, 1x10^9-1x10^10+ high dose Interleukin-2, 2.0x10^6 cells/kg (9-12 days culture), 2.0x10^6 cells/kg (Moderate chemo), 2.0x10^6 cells/kg (Reduced chemo), 2.5x10^6 cells/kg, 6.0x10^6 cells/kg (Reduced chemo) | Intervention Type: DRUG; Name: Aldesleukin; Assigned to Arm(s): 1x10^9-1x10^10 + high dose Retreat, 1x10^9-1x10^10+ high dose Interleukin-2 | Intervention Type: DRUG; Name: Fludarabine; Assigned to Arm(s): 1.0x10^6 cells/kg (Reduced chemo), 2.0x10^6 cells/kg (9-12 days culture), 2.0x10^6 cells/kg (Moderate chemo), 2.0x10^6 cells/kg (Reduced chemo), 6.0x10^6 cells/kg (Reduced chemo) | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): 1.0x10^6 cells/kg (Reduced chemo), 2.0x10^6 cells/kg (9-12 days culture), 2.0x10^6 cells/kg (Moderate chemo), 2.0x10^6 cells/kg (Reduced chemo), 6.0x10^6 cells/kg (Reduced chemo)
C: Arm Label: Human CD19 targeted T Cells Injection; Type: EXPERIMENTAL; Interventions: Drug: Human CD19 targeted T Cells Injection | Intervention Type: DRUG; Name: Human CD19 targeted T Cells Injection; Assigned to Arm(s): Human CD19 targeted T Cells Injection
D: Arm Label: ACTR087, in combination with rituximab; Type: EXPERIMENTAL; Interventions: Biological: ACTR087, Biological: rituximab | Intervention Type: BIOLOGICAL; Name: ACTR087; Assigned to Arm(s): ACTR087, in combination with rituximab | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): ACTR087, in combination with rituximab

Answer: A